These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The use of dosimetry in the treatment of differentiated thyroid cancer. Lassmann M; Hänscheid H; Verburg FA; Luster M Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):107-15. PubMed ID: 21386785 [TBL] [Abstract][Full Text] [Related]
24. The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy. Viswanathan AN; Erickson BA; Ibbott GS; Small W; Eifel PJ Brachytherapy; 2017; 16(1):68-74. PubMed ID: 28109633 [TBL] [Abstract][Full Text] [Related]
25. Radiation protection in therapy with radiopharmaceuticals. Hosono M Int J Radiat Biol; 2019 Oct; 95(10):1427-1430. PubMed ID: 30265162 [No Abstract] [Full Text] [Related]
26. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741 [TBL] [Abstract][Full Text] [Related]
28. Imaging technologies for radionuclide dosimetry. Ott RJ Phys Med Biol; 1996 Oct; 41(10):1885-94. PubMed ID: 8912368 [TBL] [Abstract][Full Text] [Related]
29. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Baechler S; Hobbs RF; Prideaux AR; Wahl RL; Sgouros G Med Phys; 2008 Mar; 35(3):1123-34. PubMed ID: 18404947 [TBL] [Abstract][Full Text] [Related]
30. Radionuclide therapy of tumors: general aspects and considerations. Hoefnagel CA Int J Biol Markers; 1993; 8(3):172-9. PubMed ID: 8277209 [TBL] [Abstract][Full Text] [Related]
31. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387 [TBL] [Abstract][Full Text] [Related]
32. Contributions of nuclear medicine to the therapy of malignant tumors. Feinendegen LE Strahlenther Onkol; 1991 Nov; 167(11):619-27. PubMed ID: 1962275 [TBL] [Abstract][Full Text] [Related]
33. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides. Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626 [TBL] [Abstract][Full Text] [Related]
34. Radionuclide cancer therapy. Hoefnagel CA Ann Nucl Med; 1998 Apr; 12(2):61-70. PubMed ID: 9637275 [TBL] [Abstract][Full Text] [Related]
36. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. Emfietzoglou D; Kostarelos K; Sgouros G J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529 [TBL] [Abstract][Full Text] [Related]
37. [Radiation-dosimetry studies after endolymphatic radionuclide therapy]. Pfannenstiel P Med Welt; 1974 Jun; 25(23):1038-42. PubMed ID: 4369658 [No Abstract] [Full Text] [Related]
38. Estimating uptake in liver and abdominal tumours for radionuclide therapy dosimetry. Bartlett ML; Macfarlane DJ Nucl Med Commun; 2002 Aug; 23(8):743-8. PubMed ID: 12124479 [TBL] [Abstract][Full Text] [Related]
39. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048 [TBL] [Abstract][Full Text] [Related]